12:00 AM
 | 
Jul 06, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Afinitor everolimus: Additional Phase II data

Additional data from the open-label, international Phase II RADIANT-1 trial in 160 patients showed that Afinitor everolimus plus Sandostatin LAR decreased tumor size in 84% of patients compared with 60% of those receiving Afinitor alone. The company previously...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >